[1] Gutin PH,Posner JB.Neuro-oncology:Diagnosis and management of cerebral gliomas-past,present,and future.Neurosurgery,2000 ,47 (1):1-8.
[2] Louis DN, Ohgaki H, Wiestler OD,et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007,114: 97-109.
[3] 王洪林,陈剑,朱虹,等.尼妥珠单抗联合术后同步放化疗治疗术后残留脑胶质瘤的初步研究[J].中华临床医师杂志(电子版),2013 ,(6):2689‐2 692.
[4] Reni M,Cozzarini C,Panucci MG,et al.Irradiation fields and dosesin glioblastoma multiforme: are current stantdards adequate[J].Tumori,2001,87(2): 85- 90.
[5] Sarica FB, Cekinmez M, Tufan K, et al. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian J Neurosurg, 2012,7: 181-190.
[6] Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys, 2012,83: 93-99.
[7] 汪洋,潘力,毛颖,等.尼妥珠单抗联合放疗加同期替莫唑胺治疗高分级胶质瘤的初步研究[J].中国癌症杂志.2009,19(11):856-860.
[8]周绍兵,刘阳晨,高飞,等.恶性脑胶质瘤术后替莫唑胺化疗联合适形放疗的疗效观察[J].现代肿瘤医学,2008,16(01):34.35.
[9] Gerson SL.MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer, 2004,4: 296-307. |